# Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

> **NCT00423670** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 765 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** boceprevir (SCH 503034)
- **DRUG:** peginterferon-alfa 2b (PegIntron)
- **DRUG:** ribavirin
- **DRUG:** ribavirin (low-dose)

## Key facts

- **NCT ID:** NCT00423670
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-08
- **Final completion:** 2008-11
- **Target enrollment:** 765 (ACTUAL)
- **Last updated:** 2017-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423670, "Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00423670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*